- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02649972
Single-agent Cobimetinib for Adults With Histiocytic Disorders
Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed histiocytic disorder or histologic findings compatible with a histiocytic disorder in the context of confirmatory radiologic findings confirmed by the enrolling institution.
One of the following:
- Documentation of BRAF V600E mutation and inability to access of BRAF inhibitor or prior treatment with a BRAF inhibitor discontinued due intolerable side effects or toxicity prior to progression, -OR-
- Documentation of wild-type BRAF V600 mutational status
- Patients with BRAF-mutated ECD/LCH who have had disease progression on BRAF inhibitor therapy would be eligible but would require tissue biopsy (or available tissue) for genotyping before participating.
- Measurable disease according to PET Response Criteria, confirmed by the MSK investigator radiologist, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria
- Histiocytic disorder must be (a) multi-system disease or (b) disease that is recurrent or refractory to standard therapies, or (c) single-system disease with that is unlikely to benefit from conventional and less toxic therapies, based on the best available evidence (for example, CNS or cardiac infiltration, retroperitoneal fibrosis, prior chemotherapy, or other medical history or co-morbidities, etc)
- Life expectancy > 12 weeks
- Age ≥ 16 years
- ECOG performance status ≤ 3 (May be converted from Karnofsky Performance Status)
Adequate bone marrow function as indicated by the following:
- ANC > 1000/uL
- Platelets ≥ 50,000/uL
- Hemoglobin ≥ 8.5 g/dL.
- Patients with cytopenias below these thresholds deemed to be the result of disease will be considered eligible.
Adequate renal function, as indicated by:
- creatinine ≤ 1.5 the upper limit of normal (ULN) -OR-
- Estimated creatinine clearance of > 50 ml/min
- As for #7, patients with renal dysfunction deemed to be the result of disease will be considered eligible.
- Adequate liver function, as defined by bilirubin ≤ 1.5 ULN
- AND AST/ALT < 3 ULN
- Ability to swallow pills
- Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
- Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. Effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the Investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- Patients must be willing to consent for protocol #12-245 for IMPACT testing (for MSK patients ONLY).
Exclusion Criteria:
- Prior treatment with a MEK inhibitor
- Active infection requiring intravenous antibiotics
- Pregnant, lactating or breast feeding women
- Prior radiation therapy within the last 14 days
- Unwillingness or inability to comply with study and follow-up procedures.
- Any foods/supplements that are strong inhibitors or inducers of CYP3A are prohibited at least 7 days prior to initiation of and during study treatment
- History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, RVO, or neovascular macular degeneration
The risk factors for RVO are listed below. Exclusion should be considered by clinical discretion if they have the following conditions:
- Uncontrolled glaucoma with intra-ocular pressures > 21mmHg
- Serum cholesterol ≥ Grade 2
- Hypertriglyceridemia ≥ Grade 2
- Hyperglycemia ≥ Grade 2
History of clinically significant cardiac dysfunction, unless deemed to be the direct result of disease, including the following:
- Current unstable angina
- Symptomatic congestive heart failure of NYHA class 2 or higher
- Uncontrolled hypertension ≥ Grade 2 (patients with a history hypertension controlled with anti-hypertensives to ≤ Grade 2 are eligible).
- Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or below 50%
- Uncontrolled arrhythmias
- Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack within the previous 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cobimetinib
This is an open-label, multicenter, phase II study exploring the efficacy and safety of single-agent Cobimetinib in patients with histiocytic disorders whose tumors are 1) BRAFV600 wildtype or 2) BRAFV600E mutant and are intolerant to, or unable to access, BRAF inhibitors.
Visits during the treatment period are to be completed on Day 1, Day 15 (this visit can be by telephone), Day 29, and every 28 days thereafter.
For patients treated on the study for six months, at the discretion of the Principal Investigator, visits can be spaced out to every 56 days (every 2 cycles instead of every cycle).
After 24 cycles of treatment, if imaging demonstrates sustained stability in the opinion of the principal investigator, tumor assessments can be performed ever 1 year.
|
Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle.
Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months.
In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study.
Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals.
Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse.
Participants will re-sign consent upon rechallenging.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Overall Response
Time Frame: 1 year
|
by PET Response Criterial (PRC), with a dichotomous BOR of CR or PR versus neither of those.
Assuming we use this binary endpoint of response, defined as best overall response of CR or PR versus not using the PET Response Criteria (PRC), a sample size of 18 patients provides 90% power to test the hypothesis that the response rate is promising (defined as 35% or higher) against a non-promising rate of 10% or lower.
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Eli Diamond, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-216
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Histiocytic Disorders
-
Memorial Sloan Kettering Cancer CenterBioMed Valley Discoveries, IncRecruiting
-
Mayo ClinicRecruiting
-
Dana-Farber Cancer InstituteCelgeneActive, not recruitingLangerhans Cell Histiocytosis (LCH) | Histiocytoses Erdheim-chester Disease | Histiocytic Sarcoma (HS)United States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLCSuspendedLymphoma | Histiocytic Sarcoma | Follicular Dendritic Cell Sarcoma | Interdigitating Dendritic Cell SarcomaUnited States
-
Far Eastern Memorial HospitalUnknownLymphoma | Kikuchi's DiseaseTaiwan
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory Plasma Cell Myeloma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Non-Hodgkin Lymphoma | Refractory Histiocytic and Dendritic Cell Neoplasm | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell MyelomaUnited States
-
University of Alabama at BirminghamRecruitingHistiocytosis | Langerhans Cell Histiocytosis | Erdheim-Chester Disease | Rosai Dorfman Disease | Xanthogranuloma | Malignant HistiocytosesUnited States
-
Gilead SciencesCompletedNon-Hodgkin's Lymphoma | Lymphoma, Diffuse | Lymphoma, Diffuse, Mixed Lymphocytic-HistiocyticFrance, United Kingdom
-
Carl AllenBaylor College of Medicine; Genentech, Inc.; North American Consortium for HistiocytosisRecruitingHistiocytic Sarcoma | Juvenile Xanthogranuloma | Histiocytic Disorders, Malignant | Erdheim-Chester Disease | Langerhan's Cell Histiocytosis | Rosai Dorfman Disease | Neuro-Degenerative DiseaseUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedLangerhans Cell Histiocytosis | Erdheim-Chester Disease | Histiocytic DisordersUnited States
Clinical Trials on Cobimetinib
-
University of UtahGenentech, Inc.RecruitingChronic Myelomonocytic Leukemia (CMML)United States
-
University of ArkansasGenentech, Inc.RecruitingArteriovenous Malformations (Extracranial)United States
-
ImmVira Pharma Co. LtdSuspendedMelanoma | Malignant MelanomaUnited States
-
Carl AllenBaylor College of Medicine; Genentech, Inc.; North American Consortium for HistiocytosisRecruitingHistiocytic Sarcoma | Juvenile Xanthogranuloma | Histiocytic Disorders, Malignant | Erdheim-Chester Disease | Langerhan's Cell Histiocytosis | Rosai Dorfman Disease | Neuro-Degenerative DiseaseUnited States
-
Genentech, Inc.Completed
-
Genentech, Inc.Completed
-
Genentech, Inc.CompletedNeoplasmsUnited States, Spain
-
Hoffmann-La RocheCompletedSolid TumorsUnited States, Spain, Germany, France, Israel, Italy, United Kingdom
-
Genentech, Inc.Completed
-
Genentech, Inc.CompletedHealthy VolunteerUnited States